Cycurion, Inc. Announces $6 Million Contract Award by Major Municipal Transportation Agency
MCLEAN, Va., April 29, 2025 (GLOBE NEWSWIRE) -- Cycurion (Nasdaq: CYCU) ('Cycurion' or the 'Company'), a trusted leader in IT cybersecurity solutions and AI, announces it has been awarded a $6 million contract by a major municipal transportation agency. Under this contract, Cycurion will deliver a wide range of professional consulting services, including Audit and Cybersecurity Services, Organizational Change Management Consulting, Data Analytics, and Information Technology Services. The Scope of Work also potentially includes the integration of Cycurion's proprietary ARx platform to further enhance operational and cybersecurity capabilities.
Cycurion brings extensive transportation sector expertise, combined with a strong track record in defining and measuring organizational performance to address deficiencies. Specific services provided will include Risk and Vulnerability Assessments, Regulatory Compliance Analysis, Enterprise Cybersecurity Strategy Development, Testing, and Vulnerability Management.
'The contract with this major municipal transportation agency demonstrates the utility of our full range of capabilities within the municipal transportation sector, and represents an important expansion into that vertical,' said L. Kevin Kelly, CEO of Cycurion. 'This award further highlights our strategic growth and ongoing commitment to helping our clients manage risk, drive innovation, and achieve operational excellence. We look forward to leveraging our full team's broad resources and deep industry expertise to deliver best-in-class solutions.'
Cycurion continues to drive its overarching strategy to expand its presence among the broader public sector services market – including that of transportation – along with the broadening of its service offerings to include higher value IT and leading cybersecurity services.
About Cycurion
Based in McLean, Virginia, Cycurion (NASDAQ: CYCU) is a forward-thinking provider of IT cybersecurity solutions and AI, committed to delivering secure, reliable, and innovative services to clients worldwide. Specializing in cybersecurity, program management, and business continuity, Cycurion harnesses its AI-enhanced ARx platform and expert team to empower clients and safeguard their operations. Along with its subsidiaries, Axxum Technologies, Cloudburst Security, and Cycurion Innovation, Inc., Cycurion serves government, healthcare, and corporate clients with a commitment to securing the digital future.
Forward Looking Statements
This press release contains statements that are forward-looking statements as defined within the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements relating to the operations and prospective growth of Cycurion's business.
Many factors could cause Cycurion's actual results, performance, or achievements to be materially different from any future results, performance, or achievements described in this press release, including words such as 'continue', 'expect', 'intend', 'will', 'hope', 'should', 'would', 'may', 'potential', and other similar expressions. Such factors could include, among others, those detailed in its Registration Statement on Form S-4 and in its Annual Report on Form 10-K, each as filed with the Securities and Exchange Commission (the 'SEC'). Should one or more of these risks or uncertainties materialize, or should the assumptions set out in the section entitled 'Risk Factors' in those filings with the SEC underlying those forward-looking statements prove incorrect, actual results may vary materially from those described herein. These forward-looking statements are made as of the date of this press release and Cycurion does not intend, and does not assume any obligation, to update these forward-looking statements, except as required by law. Cycurion cannot assure that such statements will prove to be accurate as actual results, and future events could differ materially from those anticipated in such statements. Individuals are cautioned that forward-looking statements are not guarantees of future performance and, accordingly, investors are cautioned not to put undue reliance on forward-looking statements due to the inherent uncertainty therein.
Investor Contact:
CORE IR
[email protected]
Media Contact:
Phone: (703) 555-0123
Email: [email protected]
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
19 minutes ago
- Yahoo
BofA Raises Zscaler's (ZS) PT to $340 Amid Rising Platform Adoption
Zscaler Inc. (NASDAQ:ZS) is one of the 10 best growth stocks to buy according to billionaires. On June 9, Bank of America analyst Tal Liani raised his price target on Zscaler to $340 from $285, while maintaining a Buy rating, following the company's CEO, Jay Chaudhry's, presentation at the Bank of America's 2025 Global Technology Conference (GTC). The analyst highlighted sustained customer demand and increasing platform adoption as key factors contributing to the higher valuation. A computer engineer analyzing a server network for cyber security threats. On June 5, management highlighted several positive trends during the GTC event. In the last quarter, over 70% of new annual contract value (ACV) came from upselling to existing clients, while new logo ACV grew 40% year-over-year. Zscaler Inc. (NASDAQ:ZS) is expanding its reach beyond core secure web gateway services, with strong traction in data security and Agentic operations now representing nearly $1 billion in annual recurring revenue (ARR). Notably, data security alone accounted for $350 million in ARR last quarter. Its recent acquisition of Airgap Networks highlights a deeper investment in cybersecurity advancements. While competition and pricing pressure remain, Zscaler's product differentiation and focus on efficiency appear to be supporting its growth outlook. In Liani's view, rising demand for Zero Trust solutions justifies a higher multiple, primarily as Zscaler executes well on both innovation and customer expansion. Zscaler Inc. (NASDAQ:ZS) is a provider of cloud-based cybersecurity solutions. Its Zero Trust architecture ensures secure connections between users, devices, and applications, regardless of location. While we acknowledge the potential of ZS as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None.
Yahoo
20 minutes ago
- Yahoo
Nvidia (NVDA) Continues to Fire on All Cylinders
Nvidia Corp. (NASDAQ:NVDA) is one of the 10 best growth stocks to buy according to billionaires. Today, Nvidia's dominance in powering data centers and AI infrastructure is virtually uncontested. The demand for its GPUs not only boosted the growth of AI-driven applications but also led to tremendous growth for the company. In fiscal year 2021, the Gaming segment accounted for approximately 50% of total revenue. Over the next four years, the Data Center business surpassed it, accounting for around 89% of total revenue, while Gaming's contribution declined to around 9% by 2025. At its recently concluded GTC conference in Paris, the company highlighted its collaboration with European telecommunications companies, cloud service providers, and supercomputing centres in building AI infrastructure in the region. This accelerated investment by the EU is also expected to include building 20 AI Factories, among which 5 are Gigafactories. Therefore, Nvidia is expected to continue running at full speed. While the stock seems to be taking a breather in 2025 after the 170% surge in 2024, the majority of the street remains bullish, with the consensus 1-year median price target still indicating over 20% upside. Among the bullish voices is Oppenheimer analyst Rick Schafer, who on June 15, reiterated a Buy rating on Nvidia with an unchanged price target of $175. Before that, on June 12, DBS analyst Fang Boon Foo reiterated a Buy rating on Nvidia Corp. (NASDAQ:NVDA) but revised the price target to $160 from $175. The analyst highlighted that Nvidia's recent partnership with Mistral AI, a French company, and its expansion plans in Europe support Nvidia's solid market position. Although he lowered the price target, the analyst still sees strong growth potential for Nvidia, and cited healthy demand, solid margins, and a strong capital spending cycle across major tech firms as key drivers for the stock's long-term performance. Nvidia Corp. (NASDAQ:NVDA) is a leading innovator in the design and production of graphics processing units (GPUs), system-on-a-chip (SoC) solutions, and AI-driven hardware and software. The company's GPUs are used in gaming, high-performance computing, AI training, and inference and serve as the backbone of data center infrastructure worldwide. While we acknowledge the potential of NVDA as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
20 minutes ago
- Yahoo
TransMedics (TMDX) Continues to Scale Innovation in Organ Transplant Care
TransMedics Group Inc. (NASDAQ:TMDX) is one of the 10 best growth stocks to buy according to billionaires. The stock has had a tremendous year so far, with share price gains of 129%, leading other stocks in this list by a considerable margin, as none of the other stocks here have even reached 100%. In 2024, the company's revenue surged a robust 83%, and the street expects it to post a solid 31% growth in FY 2025. The company is also likely to experience significantly improved profitability, as consensus EPS forecasts a 77% growth this year and a 38% growth next year. A doctor performing a living donor kidney transplant in a hospital operating room, emphasizing the importance of medical advancements. On June 9, Canaccord Genuity analyst William Plovanic reaffirmed a Buy rating on TransMedics Group Inc. (NASDAQ:TMDX) with an unchanged price target of $129. This reaffirmation follows the company's June 9 presentation at the Goldman Sachs Global Healthcare Conference, where the company reaffirmed the strategy behind its industry-leading position in organ transplantation. Its execution continues to support a positive outlook, with management sharing tangible progress toward its long-term targets. At the centre of the story is the National OCS Program (NOP), which now drives nearly all company revenue, enabling TransMedics to offer a full-service, end-to-end transplant logistics and technology solution. This model has not only boosted transplant volumes but also established a critical advantage that competitors have yet to replicate. The company is targeting $1.2 billion in revenue and a 30% operating margin by 2028, driven by the expanded adoption of its Organ Care System and the upcoming next-generation platforms. Notably, its leadership in the DCD (donation after circulatory death) heart category, which now makes up about half of all U.S. heart donors, reflects its role in expanding the donor pool. TransMedics Group Inc. (NASDAQ:TMDX) is well-positioned to introduce new platforms for heart, lung, and kidney care in the coming years, including a Gen 3 system designed for greater portability and scalability. With strong clinical data and operational depth, the company appears well-positioned to hit its 10,000 annual transplants milestone by 2028 and continue growing from there. Management expects its kidney platform to launch by 2027 and aims to achieve 20,000 to 30,000 transplants over the next three to five years. TransMedics Group Inc. (NASDAQ:TMDX) is a commercial-stage medical technology company offering organ transplant therapy for patients with end-stage organ failure across multiple disease states. While we acknowledge the potential of TMDX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None. Sign in to access your portfolio
